Table 1: Age presentation group analyses.

 

< 20 years

N = 8

20 to < 30

N = 22

30 to < 40

N = 22

40 to < 50

N = 30

50 to < 60

N = 53

60 to < 70

N = 46

> 70

N = 29

Gender (p = 0.791)

 

 

 

 

 

 

 

Female

3 (37.5)

12 (54.5)

11 (50.0)

11 (36.7)

21 (39.6)

23 (50.0)

13 (44.8)

Male

5 (62.5)

10 (45.5)

11 (50.0)

19 (63.3)

32 (60.4)

23 (50.0)

16 (55.2)

Ethnic (p = 0.046*)

 

 

 

 

 

 

 

Chinese

3 (37.5)

7 (31.8)

11 (50.0)

15 (50.0)

29 (54.7)

28 (60.9)

18 (62.1)

Malay

4 (50.0)

13 (59.1)

7 (31.8)

4 (13.3)

14 (26.4)

12 (26.1)

4 (13.8)

Indian

0 (0.0)

0 (0.0)

1 (4.5)

6 (20.0)

5 (9.4)

1 (2.2)

3 (10.3)

Others

1 (12.5)

2 (9.1)

3 (13.6)

5 (16.7)

5 (9.4)

5 (10.9)

4 (13.8 )

Site (p = 0.178)

 

 

 

 

 

 

 

Nodal

2 (25.0)

11 (50.0 )

6 (27.3 )

14 (46.7)

30 (56.6)

23 (50.0)

10 (34.5)

Extranodal

6 (75.0)

11 (50.0)

16 (72.7)

16 (53.3)

23 (43.4)

23 (50.0)

19 (65.5)

Lymphoma Subtype

 

 

 

 

 

 

 

DLBCL, NOS

2 (25.0)

6 (27.2)

12 (54.5)

9 (30.0)

30 (56.6)

28 (60.9)

20 (69.0)

Plasmablastic

1 (12.5)

0 (0.0)

0 (0.0)

1 (3.3)

1 (1.9)

0 (0.0)

1 (3.4)

FL

0 (0.0)

0 (0.0)

1 (4.5)

8 (26.7)

8 (15.1)

4 (8.7)

0 (0.0)

MZL

0 (0.0)

0 (0.0)

3 (13.6)

2 (6.7)

2 (3.8)

6 (13.0)

3 (10.3)

MCL

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

2 (3.8)

2 (4.3)

2 (6.9)

BL

3 (37.5)

0 (0.0)

2 (9.1)

1 (3.3)

0 (0.0)

0 (0.0)

0 (0.0)

SLL

0 (0.0)

0 (0.0)

0 (0.0)

1 (3.3)

1 (1.9)

1 (2.2)

0 (0.0)

Lymphoblastic Lymphoma

0 (0.0)

0 (0.0)

1 (4.5)

0 (0.0)

1 (1.9)

0 (0.0)

1 (3.4)

B-cell NHL (No category)

0 (0.0)

1 (4.5)

1 (4.5)

2 (6.7)

2 (3.8)

1 (2.2)

2 (6.9)

T-cell NHL

0 (0.0)

0 (0.0)

1 (4.5)

3 (10.0)

4 (7.5)

2 (4.3)

0 (0.0)

HL

2 (25.0)

15 (68.2)

1 (4.5)

3 (10.0)

2 (3.8)

2 (4.3)

0 (0.0)